LONG TERM OUTCOMES FOR WOMEN WITH BREAST CA IN SITU

描述(改编自申请者摘要)：本项目建议 研究研究参与者的长期健康和生活方式结果 女性乳腺原位癌的人群病例/对照研究 研究人群包括所有被诊断为女性BCI的病例 康涅狄格州居民自1994年9月15日至1998年3月14日 以及也从该州选择的一系列随机数字拨号控件 康涅狄格州。病例年龄将在20岁至84岁之间 诊断，而对照在五年内与病例的频率相匹配 间隔时间。目前的回应率表明，最终样本将包括 约1200例病例和1200例对照。基线电话采访有 已经与研究对象一起进行了研究，并包括关于 癌症家族史、妊娠和月经史、激素替代 治疗、口服避孕药的使用以及社会人口变量。在……里面 此外，正在为每个病例收集石蜡包埋的肿瘤组织，以 雌激素(ER)、孕激素(PR)、P53和HER-2/neu的检测 用免疫组织化学的方法。 目前的申请建议在五年后重新联系研究参与者 从第一次诊断/第一次接触开始。研究对象将再次成为 应邀参加一次电话采访，以收集有关 初始问卷中涵盖的选定主题领域，如医疗 病史(乳房复发、第二次癌症)、家族史、怀孕和 月经史也是为了收集有关选定指标的新信息 幸福感和功能，包括抑郁、职业、性关系和 保险公司。此外，我们将要求妇女向我们提供口腔标本。 用于BRCA1/BRCA2测试。研究的目标如下：1)提供 同侧和对侧的年度和五年累计估计数 乳腺癌风险、区域或远处转移疾病风险、继发癌症 对于被诊断为BCIS的妇女来说，风险和死亡都是如此。2)评估 通过检查病例和对照之间的差异来研究BCIS对心理社会的影响 关于最初五年后幸福感和功能的选定测量 招聘。3)衡量临床变量之间的关联，例如 激素受体阳性和粉刺样坏死对病例患者预后的影响。 4)评估年龄和年龄等流行病危险因素之间的联系 乳腺癌家族史和预后，5)提供以人群为基础的 BCIS中BRCA1和BRCA2的估计。6)验证/评估当前 胆管细胞癌的临床组织病理学分类方案 结果。该项目是评估 女性BCIS患者的生存经历。这些数据的独特之处在于 将收集流行病学、生物学和临床变量 使我们能够研究这些变量与长期 结果。

DESCRIPTION (Adapted from the Applicant's Abstract): This project proposes to study the long-term health and lifestyle outcomes for study participants of a population-based case/control study of female breast carcinoma in-situ (BCIS). The study population includes all cases of female BCIS diagnosed among residents of the state of Connecticut from September 15, 1994 to March 14, 1998 as well as a series of random-digit-dial controls also selected from the state of Connecticut. Cases will be between the ages of 20 and 84 years at time of diagnosis while controls are frequency matched to the cases by five-year intervals. Current response rates indicate that the final sample will include approximately 1200 cases and 1200 controls. Baseline telephone interviews have already been conducted with the study subjects and include information on family history of cancer, pregnancy and menstrual history, hormone replacement therapy, oral contraceptive use, as well as socio-demographic variables. In addition, paraffin-embedded tumor tissue is being collected for each case to test for the presence of estrogen (ER), progesterone (PR), p53, and HER-2/neu using immunohistochemistry. The current application proposes to recontact study participants at five years from time of initial diagnosis/initial contact. Study subjects will again be asked to participate in a telephone interview to collect updated information on selected topic areas covered in the initial questionnaire such as medical history (breast recurrences, second cancers), family history, pregnancy and menstrual history but also to collect new information on selected measures of well-being and functioning including depression, career, sexual relations, and insurance. In addition, we will ask women to provide us with buccal specimens for BRCA1/BRCA2 testing. The goals of the study are as follows: 1) To provide annual and five-year cumulative estimates of ipsilateral and contralateral breast cancer risk, regional or distant metastatic disease risk, second cancer risk as well as death for women diagnosed with BCIS. 2) To assess the psychosocial impact of BCIS by examining differences between cases and controls on selected measures of well-being and functioning at five years after original recruitment. 3) To measure the association between clinical variables such as hormone receptor positivity and comedo necrosis on outcome for case subjects. 4) To assess the association between epidemiologic risk factors such as age and a family history of breast cancer with outcome, 5) To provide population-based estimates of BRCA1 and BRCA2 in BCIS. 6) To validate/evaluate current histopathologic classification schemes for BCIS with respect to clinical outcome. This project represents one of the first large attempts to assess the survivorship experience of women with BCIS. The data are unique in that epidemiologic, biologic and clinical variables will have been collected allowing us to study the relationship of these variables with long term outcome.